$SEEL
Seelos Therapeutics Inc Stock $seel

$seel Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-K Financial Statement

#000101749118000026 Filed on March 01, 2018

Income Statement

Concept	2018 Q1	2017 Q4	2017
Revenue	$0.00	$0.00	$511.0K
YoY Change			-91.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.140M	$2.410M	$7.210M
YoY Change	48.61%	26.84%	-7.33%
% of Gross Profit
Research & Development	$217.0K	$240.0K	$3.463M
YoY Change	-47.33%	-60.66%	-41.11%
% of Gross Profit
Depreciation & Amortization	$13.00K	$20.00K	$117.0K
YoY Change	-76.79%	-118.18%	10.38%
% of Gross Profit
Operating Expenses	$2.352M	$2.650M	$10.68M
YoY Change	26.93%	5.58%	-21.92%
Operating Profit	-$2.352M		-$10.68M
YoY Change	26.93%		-21.92%
Interest Expense	$0.00	-$50.00K	-$83.00K
YoY Change	-100.0%	-102.27%	-91.56%
% of Operating Profit
Other Income/Expense, Net	$81.00K	$100.0K	-$1.074M
YoY Change	-105.22%		-117.86%
Pretax Income	-$2.270M	-$2.600M	-$11.75M
YoY Change	-33.24%	712.5%	53.39%
Income Tax
% Of Pretax Income
Net Earnings	-$2.271M	-$2.450M	$321.0K
YoY Change	-128.13%	716.67%	-104.32%
Net Earnings / Revenue			62.82%
Basic Earnings Per Share
Diluted Earnings Per Share	-$4.283M	-$4.804M	$800.0K
COMMON SHARES
Basic Shares Outstanding	16.34M shares	15.22M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q1	2017 Q4	2017
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.680M	$6.330M	$6.330M
YoY Change	51.06%	202.87%	202.87%
Cash & Equivalents	$5.678M	$6.331M	$6.330M
Short-Term Investments
Other Short-Term Assets	$240.0K	$260.0K	$260.0K
YoY Change	-82.61%	-83.23%	-83.23%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$5.918M	$6.592M	$6.590M
YoY Change	15.0%	81.4%	81.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$66.00K	$79.00K	$80.00K
YoY Change	-53.52%	-51.83%	-50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$36.00K	$35.00K	$40.00K
YoY Change	-44.62%	-41.67%	-95.56%
Total Long-Term Assets	$102.0K	$114.0K	$120.0K
YoY Change	-50.72%	-89.31%	-88.79%
TOTAL ASSETS
Total Short-Term Assets	$5.918M	$6.592M	$6.590M
Total Long-Term Assets	$102.0K	$114.0K	$120.0K
Total Assets	$6.020M	$6.706M	$6.710M
YoY Change	12.46%	42.68%	42.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$340.0K	$60.00K	$60.00K
YoY Change	-30.61%	-92.11%	-92.11%
Accrued Expenses	$929.0K	$650.0K	$1.510M
YoY Change	70.46%	-51.24%	-22.56%
Deferred Revenue		$12.00K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.690M	$1.583M	$1.580M
YoY Change	-34.75%	-85.98%	-86.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$42.00K	$58.00K	$750.0K
YoY Change	-37.31%	-23.68%	-18.48%
Total Long-Term Liabilities	$42.00K	$58.00K	$750.0K
YoY Change	-37.31%	-23.68%	-18.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.690M	$1.583M	$1.580M
Total Long-Term Liabilities	$42.00K	$58.00K	$750.0K
Total Liabilities	$1.732M	$2.335M	$2.340M
YoY Change	-61.6%	-80.89%	-80.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$318.3M	-$316.0M
YoY Change	3.25%	-0.1%
Common Stock	$322.5M	$320.4M
YoY Change	4.36%	3.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.288M	$4.371M	$4.370M
YoY Change
Total Liabilities & Shareholders Equity	$6.020M	$6.706M	$6.710M
YoY Change	12.46%	42.68%	42.77%

Cashflow Statement

Concept	2018 Q1	2017 Q4	2017
OPERATING ACTIVITIES
Net Income	-$2.271M	-$2.450M	$321.0K
YoY Change	-128.13%	716.67%	-104.32%
Depreciation, Depletion And Amortization	$13.00K	$20.00K	$117.0K
YoY Change	-76.79%	-118.18%	10.38%
Cash From Operating Activities	-$310.0K	-$2.480M	-$10.47M
YoY Change	-88.52%	-8.49%	-19.88%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities		$210.0K	$12.21M
YoY Change			4260.71%
Cash From Investing Activities		$210.0K	$12.21M
YoY Change		2000.0%	4507.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$10.73M
YoY Change			-27.29%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	70.00K	130.0K	2.500M
YoY Change	-100.98%	-115.66%	-77.28%
NET CHANGE
Cash From Operating Activities	-310.0K	-2.480M	-10.47M
Cash From Investing Activities		210.0K	12.21M
Cash From Financing Activities	70.00K	130.0K	2.500M
Net Change In Cash	-240.0K	-2.140M	4.240M
YoY Change	-114.37%	-39.38%	-335.56%
FREE CASH FLOW
Cash From Operating Activities	-$310.0K	-$2.480M	-$10.47M
Capital Expenditures		$0.00	$0.00
Free Cash Flow		-$2.480M	-$10.47M
YoY Change		-8.49%	-19.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	apri	Aggregate Liability Limitation Indemnification Claims AggregateLiabilityLimitationIndemnificationClaims	2000000	USD
CY2016Q4	apri	Deferred Tax Assets Intangible Asset Basis Difference DeferredTaxAssetsIntangibleAssetBasisDifference	3870000	USD
CY2017Q4	apri	Deferred Tax Assets Intangible Asset Basis Difference DeferredTaxAssetsIntangibleAssetBasisDifference	3658000	USD
CY2016Q4	apri	Deferred Tax Assets Operating Loss And Capital Loss Carryforwards DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards	68672000	USD
CY2017Q4	apri	Deferred Tax Assets Operating Loss And Capital Loss Carryforwards DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards	23463000	USD
CY2016Q4	apri	Deferred Tax Assets Operating Loss Carryforwards And Tax Credit Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwardsDomestic	70300000	USD
CY2017Q4	apri	Deferred Tax Assets Operating Loss Carryforwards And Tax Credit Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwardsDomestic	25400000	USD
	apri	Disposal Group Including Discontinued Operation Payments Recognized For Transition Services DisposalGroupIncludingDiscontinuedOperationPaymentsRecognizedForTransitionServices	500000	USD
	apri	Disposal Group Including Discontinued Operation Payments Recognized For Transition Services DisposalGroupIncludingDiscontinuedOperationPaymentsRecognizedForTransitionServices	500000	USD
CY2017Q1	apri	Disposal Group Including Discontinued Operations Disposal During Period Carrying Value Of Assets DisposalGroupIncludingDiscontinuedOperationsDisposalDuringPeriodCarryingValueOfAssets	1578000	USD
CY2017Q1	apri	Disposal Group Including Discontinued Operations Disposal During Period Liabilities Transferred DisposalGroupIncludingDiscontinuedOperationsDisposalDuringPeriodLiabilitiesTransferred	1186000	USD
	apri	Disposal Group Including Discontinued Operations Disposal During Period Liabilities Transferred After Closing Date DisposalGroupIncludingDiscontinuedOperationsDisposalDuringPeriodLiabilitiesTransferredAfterClosingDate	1100000	USD
CY2017Q4	apri	Entity Public Float Primary Public Offerings Of Securities Threshold EntityPublicFloatPrimaryPublicOfferingsOfSecuritiesThreshold	75000000	USD
CY2017Q1	apri	Expected Payments For Transition Services Number Of Quarterly Payments ExpectedPaymentsForTransitionServicesNumberOfQuarterlyPayments	2	payment
CY2016	apri	Gain Losseson Extinguishmentof Debt Non Cash Operating GainLossesonExtinguishmentofDebtNonCashOperating	0	USD
CY2017	apri	Gain Losseson Extinguishmentof Debt Non Cash Operating GainLossesonExtinguishmentofDebtNonCashOperating	-422000	USD
CY2016	apri	Issuance Of Common Stock And Warrants Value IssuanceOfCommonStockAndWarrantsValue	7865000	USD
CY2017	apri	Noncash Financing Activities Issuance Of Placement Agent Warrants NoncashFinancingActivitiesIssuanceOfPlacementAgentWarrants	287000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1333000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	650000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	880000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	575000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	366000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	442000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	308784000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	320343000	USD
CY2017	apri	Warrant Liability Reclassified To Stockholders Equity WarrantLiabilityReclassifiedToStockholdersEquity	798000	USD
CY2017	dei	Amendment Flag AmendmentFlag	false
CY2017	apri	Issuance Of Common Stock And Warrants Value IssuanceOfCommonStockAndWarrantsValue	10733000	USD
CY2016	apri	Noncash Financing Activities Issuance Of Placement Agent Warrants NoncashFinancingActivitiesIssuanceOfPlacementAgentWarrants	103000	USD
CY2016	apri	Noncash Financing Activities Reclassification Of Warrants To Equity NoncashFinancingActivitiesReclassificationOfWarrantsToEquity	0	USD
CY2017	apri	Noncash Financing Activities Reclassification Of Warrants To Equity NoncashFinancingActivitiesReclassificationOfWarrantsToEquity	798000	USD
CY2017Q4	apri	Number Of Product Candidates NumberOfProductCandidates	2	product
CY2016Q1	apri	Proceeds From Issuance Of Sale Of Equity Net Of Transaction Costs ProceedsFromIssuanceOfSaleOfEquityNetOfTransactionCosts	9600000	USD
CY2017Q2	apri	Proceeds From Sale Of Product Related Inventory ProceedsFromSaleOfProductRelatedInventory	709000	USD
CY2017Q2	apri	Proceeds From Sale Of Product Related Inventory ProceedsFromSaleOfProductRelatedInventory	700000	USD
CY2017Q4	apri	Public Float Primary Public Offerings Of Securities Percent Of Public Float Eligible To Be Raised If Under Threshold PublicFloatPrimaryPublicOfferingsOfSecuritiesPercentOfPublicFloatEligibleToBeRaisedIfUnderThreshold	0.3333
CY2017Q1	apri	Purchase Agreement Maximum Potential Proceeds From Divestiture PurchaseAgreementMaximumPotentialProceedsFromDivestiture	12700000	USD
CY2016Q4	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	142000	USD
CY2017Q4	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	61000	USD
CY2016	apri	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.1133
CY2017Q4	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	7084000	shares
CY2017Q4	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	3.91
CY2017	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	1.55
CY2017	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	1.60
CY2016Q4	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	15.19
CY2017Q4	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	3.91
CY2017	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice	52.50
CY2017Q4	apri	Shelf Registration Statement Available Amount ShelfRegistrationStatementAvailableAmount	100000000	USD
CY2014Q3	apri	Shelf Registration Statement Available Amount ShelfRegistrationStatementAvailableAmount	100000000	USD
CY2017	apri	Tax Cutsand Jobs Actof2017 Incomplete Accounting Changein Tax Rate Provisional Income Tax Expense Benefit TaxCutsandJobsActof2017IncompleteAccountingChangeinTaxRateProvisionalIncomeTaxExpenseBenefit	-19500000	USD
CY2017	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2017	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017	dei	Document Period End Date DocumentPeriodEndDate	2017-12-31
CY2017	dei	Document Type DocumentType	10-K
CY2017	dei	Entity Central Index Key EntityCentralIndexKey	0001017491
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16338811	shares
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2017Q2	dei	Entity Public Float EntityPublicFloat	14300000	USD
CY2017	dei	Entity Registrant Name EntityRegistrantName	APRICUS BIOSCIENCES, INC.
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017	dei	Trading Symbol TradingSymbol	APRI
CY2016Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	763000	USD
CY2017Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	58000	USD
CY2016	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	362000	USD
CY2017	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	56000	USD
CY2016Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	614000	USD
CY2017Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	863000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1747000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1138000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1392000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	289000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1747000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1138000	USD
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2848000	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8170000	shares
CY2016Q4	us-gaap	Assets Assets	4700000	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2017Q4	us-gaap	Assets Assets	6706000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	3634000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	6592000	USD
CY2016Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	1370000	USD
CY2017Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2016Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	76000	USD
CY2017Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	76000	USD
CY2016Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	130000	USD
CY2017Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	130000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3887000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2087000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6331000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1800000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4244000	USD
CY2016	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
CY2017	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	12209000	USD
CY2016	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	712000	USD
CY2017	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	105000	USD
CY2017Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	7084000	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7733205	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15217231	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7733205	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15217231	shares
CY2016Q1	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	10000000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	15000	USD
CY2016Q4	us-gaap	Customer Deposits Noncurrent CustomerDepositsNoncurrent	0	USD
CY2017Q4	us-gaap	Customer Deposits Noncurrent CustomerDepositsNoncurrent	12000	USD
CY2016	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	236000	USD
CY2017	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2016	us-gaap	Decrease In Restricted Cash DecreaseInRestrictedCash	280000	USD
CY2017	us-gaap	Decrease In Restricted Cash DecreaseInRestrictedCash	0	USD
CY2016Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	134000	USD
CY2017Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	0	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	76000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	46000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	12000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	80731000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	34385000	USD
CY2016Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5270000	USD
CY2017Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4620000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1659000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1923000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	46000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	1214000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	721000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	80731000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	34385000	USD
CY2016	us-gaap	Depreciation Depreciation	100000	USD
CY2017	us-gaap	Depreciation Depreciation	100000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	106000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	117000	USD
CY2016Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	846000	USD
CY2017Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	694000	USD
CY2017Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	700000	USD
CY2017	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	12317000	USD
CY2016Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	842000	USD
CY2017Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	0	USD
CY2017Q4	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	12709000	USD
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.15
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.02
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.81
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	3.60
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.00
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-1.65
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.34
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.02
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.04
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.05
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-2.27
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.04
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.01
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7479000	USD
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	646000	USD
CY2016Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	25000	USD
CY2017Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	25000	USD
CY2016	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-14000	USD
CY2017	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-2000	USD
CY2016	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-422000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7778000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7210000	USD
CY2016	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-7659000	USD
CY2017	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-11749000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-1.18
CY2017	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.99
CY2016	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	226000	USD
CY2017	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	12070000	USD
CY2016	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.03
CY2017	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	1.01
CY2016	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	6000	USD
CY2017	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	45000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-705000	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1340000	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-681000	USD
CY2016	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-360000	USD
CY2017	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	249000	USD
CY2016	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-40000	USD
CY2017	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-25000	USD
CY2016	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-121000	USD
CY2017	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-7000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-408000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	84000	USD
CY2016	us-gaap	Interest Expense Debt InterestExpenseDebt	1000000	USD
CY2017	us-gaap	Interest Expense Debt InterestExpenseDebt	100000	USD
CY2016	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-983000	USD
CY2017	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-83000	USD
CY2016	us-gaap	Interest Paid InterestPaid	646000	USD
CY2017	us-gaap	Interest Paid InterestPaid	92000	USD
CY2016Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	20000	USD
CY2017Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	20000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	12216000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	2335000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4700000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6706000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11294000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1583000	USD
CY2016Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1934000	USD
CY2017Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2016Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	279000	USD
CY2017Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	270000	USD
CY2016	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	712000	USD
CY2017	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	12314000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	11003000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2501000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	265000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13780000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10571000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-7433000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	300000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	321000	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6013000	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1074000	USD
CY2016Q4	us-gaap	Notes Payable Current NotesPayableCurrent	6650000	USD
CY2017Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2017	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2016	us-gaap	Operating Expenses OperatingExpenses	13672000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	10675000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-13672000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-10675000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	770000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	364000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	32000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	374000	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	500000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	300000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	177000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	14000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	60000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	35000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	76000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	58000	USD
CY2016	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-10000	USD
CY2017	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-22000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	77000	USD
CY2016Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	400000	USD
CY2016	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	641000	USD
CY2017	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1392000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	164000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	79000	USD
CY2016	us-gaap	Recapitalization Costs RecapitalizationCosts	461000	USD
CY2017	us-gaap	Recapitalization Costs RecapitalizationCosts	0	USD
CY2016	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	5000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000.0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	177000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	261000	USD
CY2017Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	11500000	USD
CY2017Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	11500000	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14762000	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10733000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2200000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7800000	USD
CY2016	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3000	USD
CY2017	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	289000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	530000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	521000	USD
CY2017	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	0	USD
CY2016	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3113000	USD
CY2017	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	7129000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5880000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3463000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-316308000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-315987000	USD
CY2016	us-gaap	Sales Revenue Net SalesRevenueNet	5763000	USD
CY2017	us-gaap	Sales Revenue Net SalesRevenueNet	511000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	1747000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	1138000	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8002
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7235
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0178
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0136
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	186000	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	247000	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	5199000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	2318000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	7084000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	228392	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	293296	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	18.91
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	46398	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.23
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	414865	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	369000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.23
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.37
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	355559	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	17.61
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	16.08
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M12D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M20D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M6D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y8M6D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1300000	USD
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	800000	USD
CY2016	us-gaap	Stock Issued1 StockIssued1	249000	USD
CY2017	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	249000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-9944000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-7516000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	4371000	USD
CY2016Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2882000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3047000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	713000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	2368000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	68000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	34000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	97000	USD
CY2017Q2	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	800000	USD
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6517000	shares
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11892000	shares
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of these consolidated financial statements in conformity with generally accepted accounting principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. The Company’s most significant estimates relate to the valuation of stock based compensation, the valuation of its warrant liabilities, the impairment of long-lived assets and valuation allowances for the Company’s deferred tax assets. The Company’s actual results may differ from these estimates under different assumptions or conditions. </font></div></div>

Files In Submission

Name	View Source	Status
0001017491-18-000026-index-headers.html	Edgar Link	pending
0001017491-18-000026-index.html	Edgar Link	pending
0001017491-18-000026.txt	Edgar Link	pending
0001017491-18-000026-xbrl.zip	Edgar Link	pending
apri-20171231.xml	Edgar Link	completed
apri-20171231.xsd	Edgar Link	pending
apri-20171231_cal.xml	Edgar Link	unprocessable
apri-20171231_def.xml	Edgar Link	unprocessable
apri-20171231_lab.xml	Edgar Link	unprocessable
apri-20171231_pre.xml	Edgar Link	unprocessable
apri12311710k.htm	Edgar Link	pending
apri123117ex1030.htm	Edgar Link	pending
apri123117ex21.htm	Edgar Link	pending
apri123117ex231.htm	Edgar Link	pending
apri123117ex311.htm	Edgar Link	pending
apri123117ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SEEL
Seelos Therapeutics Inc Stock $seel

2018 Q1 Form 10-K Financial Statement

#000101749118000026 Filed on March 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL Seelos Therapeutics Inc Stock $seel

2018 Q1 Form 10-K Financial Statement

#000101749118000026 Filed on March 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL
Seelos Therapeutics Inc Stock $seel